Cas:773122-63-7 3-amino-3-(5-bromo-2-hydroxy-3-methoxyphenyl)propanoic acid manufacturer & supplier

Chemical Name:3-amino-3-(5-bromo-2-hydroxy-3-methoxyphenyl)propanoic acid

CAS.NO:773122-63-7

Synonyms:Benzenepropanoic acid,b-amino-5-bromo-2-hydroxy-3-methoxy;RARECHEM AL BL 0240

Molecular Formula:C₁₀H₁₂BrNO₄

Molecular Weight:290.11100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:92.78000

Exact Mass:288.99500

LogP:2.33810

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Benzenepropanoic acid,b-amino-5-bromo-2-hydroxy-3-methoxy chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,RARECHEM AL BL 0240 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenepropanoic acid,b-amino-5-bromo-2-hydroxy-3-methoxy Use and application,Benzenepropanoic acid,b-amino-5-bromo-2-hydroxy-3-methoxy technical grade,usp/ep/jp grade.

Related News: The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 3-amino-3-(5-bromo-2-hydroxy-3-methoxyphenyl)propanoic acid manufacturer Any drug or medication is composed of two components. 3-amino-3-(5-bromo-2-hydroxy-3-methoxyphenyl)propanoic acid supplier This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. 3-amino-3-(5-bromo-2-hydroxy-3-methoxyphenyl)propanoic acid vendor Any drug or medication is composed of two components. 3-amino-3-(5-bromo-2-hydroxy-3-methoxyphenyl)propanoic acid factory The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful.